DUBLIN–(BUSINESS WIRE)–The “Drug Delivery in Cancer – Technologies, Markets & Companies” report from Jain PharmaBiotech has been added to ResearchAndMarkets.com’s offering. Drug delivery remains a challenge in the management of cancer. Approximately 12.5 million new cases of cancer are being diagnosed worldwide each year and considerable research is in progress for drug discovery for cancer. … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Nitric Oxide – Therapeutics, Markets and Companies” report from Jain PharmaBiotech has been added to ResearchAndMarkets.com’s offering. This report describes the latest concepts of the role of nitric oxide (NO) in health and disease as a basis for therapeutics and development of new drugs. Major segments of the market for nitric oxide-based drugs … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Personalized Medicine – Scientific & Commercial Aspects” report from Jain PharmaBiotech has been added to ResearchAndMarkets.com’s offering. The aim of personalized medicine or individualized treatment is to match the right drug to the right patient and, in some cases, even to design the appropriate treatment for a patient according to his/her genotype. This … [Read more…]

SCOTTSDALE, Ariz.–(BUSINESS WIRE)–#Clinicaltrials—VirTrial has been awarded an FDA-approved hybrid decentralized clinical trial (DCT) with Hope Biosciences. The study provides Hope Biosciences’ autologous, adipose-derived culture-expanded mesenchymal stem cells (HB-adMSCs) for the treatment of spinal cord injury/disorder (SCI/D). Study protocol incorporates remote visits via VirTrial’s telehealth platform. “After reviewing countless vendors, we found that VirTrial met our … [Read more…]

Partnership combines deep patient safety and risk management capabilities with MIDAS+ expertise ATLANTA–(BUSINESS WIRE)–Riskonnect, the leading integrated risk management software solution provider serving 1200 hospitals and thousands of other healthcare organizations, has partnered with MG Select, a professional services and strategic advisory firm, to assist companies transitioning away from legacy software platform MIDAS+. “Riskonnect has … [Read more…]

Gelest exclusive supplier of chemistry for OcuMedic proprietary drug eluting contact lens and corneal bandage MULLICA HILL, N.J.–(BUSINESS WIRE)–#Cornea—OcuMedic, Inc., the developer of new proprietary, drug-eluting soft contact lens/clear corneal bandage technology to replace eye drops, today announced it has entered into an exclusive supply agreement and received a strategic investment from Gelest, Inc., a … [Read more…]

Survey shows lack of rural broadband access equates to lack of access to health insurance and necessary medical care FERGUS FALLS, Minn.–(BUSINESS WIRE)–Communicating for America (CA), a rural advocacy organization, has released a new study that correlates the lack of high-speed internet to the lack of health insurance coverage and access to health care. The … [Read more…]

– Intravitreal ANX007 was well-tolerated and demonstrated full target engagement and inhibition of C1q in the eye for at least four weeks – – Annexon plans to advance the clinical development of ANX007 in geographic atrophy – SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Annexon Biosciences, a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “3D Bioprinting Market by Component (3D Bioprinters (Microextrusion, Inkjet, Laser), Bioink (Natural, Synthetic, Hybrid)), Material (Hydrogel, Living Cells), Application (Skin, Drug Research), End user (Biopharma, Academia) – Global Forecast to 2024” report has been added to ResearchAndMarkets.com’s offering. The 3D bioprinting market is projected to reach USD 1,647 million by 2024 from USD … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Respiratory Syncytial Virus Attachment Glycoprotein – Pipeline Review, H2 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering. The report Respiratory Syncytial Virus Attachment Glycoprotein – Pipeline Review, H2 2019, outlays comprehensive information on the Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) targeted therapeutics, complete with analysis by indications, stage of … [Read more…]